Background:

I2906 showed antimycobacterial and cytotoxic activity against mycobacterium tuberculosis.IC50 Value: Target: AntibacterialUnder in vitro conditions, I2906 showed excellent antimycobacterial activities and low cytotoxicity. In a murine model infected with M. tuberculosis H37Rv, the reductions on bacterial loads of both lungs and spleen were statistically significant (p< 0.05) between I2906-treated mice and untreated controls after 4 weeks. Further, the colony-forming unit counts in the lungs were dramatically lower (p< 0.05) than that of isoniazid-treated mice by the addition of I2906 after 8 weeks. Moreover, survival rate was increased by I2906 treatment. For multidrug-resistant strain infection, bacterial counts were reduced significantly in the lungs and spleen due to I2906 treatment in comparison with data from untreated controls (p< 0.05).

[1]. Lu, Jingning; Yue, Jun; Wu, Jing et al. In vitro and in vivo Activities of a New Lead Compound I2906 against Mycobacterium tuberculosis. Pharmacology (2010), 85(6), 365-371.